相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
Krishna R. Juluri et al.
BLOOD ADVANCES (2022)
Unity brings strength: Combination of CAR-T cell therapy and HSCT
RuiHao Huang et al.
CANCER LETTERS (2022)
CAR T cell therapy for multiple myeloma: What have we learned?
Sandra Susanibar Adaniya et al.
LEUKEMIA (2022)
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma
Taewoong Choi et al.
PHARMACOLOGY & THERAPEUTICS (2022)
Genome chaos: Creating new genomic information essential for cancer macroevolution
Julie Heng et al.
SEMINARS IN CANCER BIOLOGY (2022)
Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).
Juan Du et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS).
He Huang et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B.
Niels W.C.J. van de Donk et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma.
Matthew J. Frigault et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
David Kegyes et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Xiaomin Zhang et al.
FRONTIERS IN IMMUNOLOGY (2022)
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
Paolo Strati et al.
HAEMATOLOGICA (2021)
Sustainable Efficacy and Safety Results from Lummicar Study 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma
Wenming Chen et al.
BLOOD (2021)
Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/ or Refractory Multiple Myeloma
Carlos Fernandez de Larrea et al.
BLOOD (2021)
Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform
Adam S. Sperling et al.
BLOOD (2021)
Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Sham Mailankody et al.
BLOOD (2021)
A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma
Chunrui Li et al.
BLOOD (2021)
Identification and Development of PHE885: A Novel and Highly Potent Fully Human Anti-BCMA CAR-T Manufactured with a Novel T-Charge TM Platform for the Treatment of Multiple Myeloma
Dexiu Bu et al.
BLOOD (2021)
Rethinking mechanisms of neurotoxicity with BCMA directed therapy
Ghulam Rehman Mohyuddin et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
Oliver Van Oekelen et al.
NATURE MEDICINE (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.
Saad Z. Usmani et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The clinical study of anti-BCMA CAR-T with single-domain antibody as antigen binding domain.
Lu Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
Larry D. Anderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7
Jiro Kikuchi et al.
LEUKEMIA (2020)
Molecular basis of clonal evolution in multiple myeloma
Yusuke Furukawa et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)
Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)
George R. Nahas et al.
LEUKEMIA & LYMPHOMA (2020)
'Off-the-shelf' allogeneic CAR T cells: development and challenges
S. Depil et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
NK cells for cancer immunotherapy
Noriko Shimasaki et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
Norris Lam et al.
NATURE COMMUNICATIONS (2020)
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).
Sham Mailankody et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
Jesus G. Berdeja et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Somatic Genomic Mosaicism in Multiple Myeloma
Christine J. Ye et al.
FRONTIERS IN GENETICS (2020)
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
Meenakshi Hegde et al.
NATURE COMMUNICATIONS (2020)
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
Gils Roex et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple Myeloma
Siguo Hao et al.
BLOOD (2020)
Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma
Shaji K. Kumar et al.
BLOOD (2020)
An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma
Gang An et al.
BLOOD (2020)
Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies
Caitlin L. Costello et al.
BLOOD (2020)
Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
Hua Jiang et al.
BLOOD (2020)
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
Deepu Madduri et al.
BLOOD (2020)
Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma
Sham Mailankody et al.
BLOOD (2020)
Early and late hematologic toxicity following CD19 CAR-T cells
Shalev Fried et al.
BONE MARROW TRANSPLANTATION (2019)
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Mohamed-Reda Benmebarek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Eric L. Smith et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Chimeric antigen receptor T cell persistence and memory cell formation
Alexander D. McLellan et al.
IMMUNOLOGY AND CELL BIOLOGY (2019)
Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity
Marine Cazaux et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
A safe and potent anti-CD19 CAR T cell therapy
Zhitao Ying et al.
NATURE MEDICINE (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Jie Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics
Nasha Elavia et al.
TRANSFUSION (2019)
A Metabolism Toolbox for CAR T Therapy
Xuequn Xu et al.
FRONTIERS IN ONCOLOGY (2019)
Modulation of chimeric antigen receptor surface expression by a small molecule switch
Alexandre Juillerat et al.
BMC BIOTECHNOLOGY (2019)
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
Margot J. Pont et al.
BLOOD (2019)
Adoptive cell therapy using engineered natural killer cells
Katayoun Rezvani
BONE MARROW TRANSPLANTATION (2019)
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Shengnan Yu et al.
MOLECULAR CANCER (2019)
Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma
Jin Jie et al.
BLOOD (2019)
Chimeric antigen receptor T cell therapies for multiple myeloma
Chao Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Jennifer N. Brudno et al.
BLOOD REVIEWS (2019)
Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
Christine I. Chen et al.
BLOOD (2019)
Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications
Sandra P. Susanibar Adaniya et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
Robert Weinkove et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)
Chimeric antigen receptor T-cell therapies for lymphoma
Jennifer N. Brudno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
CD70, a novel target of CAR T-cell therapy for gliomas
Linchun Jin et al.
NEURO-ONCOLOGY (2018)
The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets
Hanley N. Abramson
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
Dok Hyun Yoon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
Eric L. Smith et al.
MOLECULAR THERAPY (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
The multiple myelomas - current concepts in cytogenetic classification and therapy
Shaji K. Kumar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
De-Xiu Bu et al.
Oncotarget (2018)
NKG2D: A Master Regulator of Immune Cell Responsiveness
Felix M. Wensveen et al.
FRONTIERS IN IMMUNOLOGY (2018)
Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.
Yarong Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.
Noopur S. Raje et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
Alexander I. Salter et al.
SCIENCE SIGNALING (2018)
CD38 as an immunotherapeutic target in multiple myeloma
Francesca Bonello et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Universal CARs, universal T cells, and universal CAR T cells
Juanjuan Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Engineering CAR-T Cells for Improved Function Against Solid Tumors
Michael A. Morgan et al.
FRONTIERS IN IMMUNOLOGY (2018)
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
Stefania Oliva et al.
FRONTIERS IN IMMUNOLOGY (2018)
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
Alfred L. Garfall et al.
JCI INSIGHT (2018)
CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma
Eric L. Smith et al.
BLOOD (2018)
Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma
Damian J. Green et al.
BLOOD (2018)
Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Tara Gregory et al.
BLOOD (2018)
Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma
Ehren Dancy et al.
BLOOD (2018)
Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists
Christopher T. Petersen et al.
BLOOD ADVANCES (2018)
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Michael Ghermezi et al.
HAEMATOLOGICA (2017)
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Michael Ghermezi et al.
HAEMATOLOGICA (2017)
Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM
Haitao Ge et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
S. K. Kumar et al.
LEUKEMIA (2017)
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
Esther Drent et al.
MOLECULAR THERAPY (2017)
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains
Leah Alabanza et al.
MOLECULAR THERAPY (2017)
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
James N. Kochenderfer et al.
MOLECULAR THERAPY (2017)
Therapeutic T cell engineering
Michel Sadelain et al.
NATURE (2017)
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Mary Philip et al.
NATURE (2017)
T memory stem cells in health and disease
Luca Gattinoni et al.
NATURE MEDICINE (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Multiple Myeloma - Current Status in Diagnostic Testing and Therapy
Michael Kehrer et al.
ZEITSCHRIFT FUR ORTHOPADIE UND UNFALLCHIRURGIE (2017)
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Levi J. Rupp et al.
SCIENTIFIC REPORTS (2017)
An oxygen sensitive self-decision making engineered CAR T-cell
Alexandre Juillerat et al.
SCIENTIFIC REPORTS (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes
Tea Gogishvili et al.
BLOOD (2017)
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors
Francesca Gay et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
γ-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct
Yong Ran et al.
EMBO MOLECULAR MEDICINE (2017)
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger et al.
CANCER CELL (2017)
The Principles of Engineering Immune Cells to Treat Cancer
Wendell A. Lim et al.
CELL (2017)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
Yu-Tzu Tai et al.
BLOOD (2016)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
Marianna Sabatino et al.
BLOOD (2016)
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
Lydia Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
The myeloma stem cell concept, revisited: from phenomenology to operational terms
Hans Erik Johnsen et al.
HAEMATOLOGICA (2016)
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
Andrea Schietinger et al.
IMMUNITY (2016)
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
Cameron J. Turtle et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies
Nathan Singh et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Chimeric antigen receptor-redirected T cells return to the bench
Claudia Geldres et al.
SEMINARS IN IMMUNOLOGY (2016)
The myeloma stem cell concept, revisited: from phenomenology to operational terms
Hans Erik Johnsen et al.
HAEMATOLOGICA (2016)
A Novel Bcma-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma
David L. Hermanson et al.
BLOOD (2016)
Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma
Sarah Nikiforow et al.
BLOOD (2016)
Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy
Benjamin W. Teh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
Designing chimeric antigen receptors to effectively and safely target tumors
Michael C. Jensen et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma
Andrew T. Hutchinson et al.
MOLECULAR IMMUNOLOGY (2015)
The pharmacology of second-generation chimeric antigen receptors
Sjoukje J. C. van der Stegen et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Engineering CAR-T cells: Design concepts
Shivani Srivastava et al.
TRENDS IN IMMUNOLOGY (2015)
γ-secretase directly sheds the survival receptor BCMA from plasma cells
Sarah A. Laurent et al.
NATURE COMMUNICATIONS (2015)
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
Cecilie Blimark et al.
HAEMATOLOGICA (2015)
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
Brian Philip et al.
BLOOD (2014)
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
Yang Xu et al.
BLOOD (2014)
Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
Markus Chmielewski et al.
IMMUNOLOGICAL REVIEWS (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
Nicoletta Cieri et al.
BLOOD (2013)
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
Christopher C. Kloss et al.
NATURE BIOTECHNOLOGY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
PD-1-and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
Victor D. Fedorov et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Eric Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
Scott Wilkie et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Paths to stemness: building the ultimate antitumour T cell
Luca Gattinoni et al.
NATURE REVIEWS CANCER (2012)
APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status
John Quinn et al.
BLOOD (2011)
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
Xiuli Wang et al.
BLOOD (2011)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
A human memory T cell subset with stem cell-like properties
Luca Gattinoni et al.
NATURE MEDICINE (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
V. Hoyos et al.
LEUKEMIA (2010)
Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
Dharminder Chauhan et al.
CANCER CELL (2009)
Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy
Marieke Griffioen et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity
Christian S. Hinrichs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
Transduction with the Antioxidant Enzyme Catalase Protects Human T Cells against Oxidative Stress
Takashi Ando et al.
JOURNAL OF IMMUNOLOGY (2008)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms - A tissue microarray study of 1,754 cases
N Kambham et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2005)
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
AJ Novak et al.
BLOOD (2004)
Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease
M Serafini et al.
HUMAN GENE THERAPY (2004)
Molecular cloning of CS1, a navel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily
KS Boles et al.
IMMUNOGENETICS (2001)
分享论文
